Clinical trial
12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA
NCT03753763 is registered in ClinicalTrials.gov with Zambon SpA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA
- Lead sponsor
- Zambon SpA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 29, 2019
- Completion date
- January 5, 2021
- Enrollment
- 49 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.